Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics
PSTX Price/Volume Stats
| Current price | $1.90 | 52-week high | $8.82 |
| Prev. close | $1.96 | 52-week low | $1.54 |
| Day low | $1.90 | Volume | 395,800 |
| Day high | $1.98 | Avg. volume | 812,564 |
| 50-day MA | $2.10 | Dividend yield | N/A |
| 200-day MA | $3.74 | Market Cap | 165.14M |
PSTX Stock Price Chart Interactive Chart >
PSTX POWR Grades
- PSTX scores best on the Value dimension, with a Value rank ahead of 97.81% of US stocks.
- PSTX's strongest trending metric is Value; it's been moving up over the last 179 days.
- PSTX ranks lowest in Momentum; there it ranks in the 3rd percentile.
PSTX Stock Summary
- Of note is the ratio of POSEIDA THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 8.18% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for POSEIDA THERAPEUTICS INC comes in at 343.03%, a number that bests 97.97% of the US stocks we're tracking.
- In terms of volatility of its share price, PSTX is more volatile than 94.28% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to POSEIDA THERAPEUTICS INC, a group of peers worth examining would be ALPN, IDYA, CARA, VIR, and TSVT.
- To check out POSEIDA THERAPEUTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001661460.
PSTX Valuation Summary
- PSTX's price/earnings ratio is -5.9; this is 121.65% lower than that of the median Healthcare stock.
- Over the past 39 months, PSTX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PSTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PSTX | 2023-09-18 | 1.1 | 1.3 | -5.9 | -10.2 |
| PSTX | 2023-09-15 | 1.1 | 1.3 | -6.1 | -10.3 |
| PSTX | 2023-09-14 | 1.2 | 1.4 | -6.3 | -10.6 |
| PSTX | 2023-09-13 | 1.1 | 1.3 | -6.2 | -10.5 |
| PSTX | 2023-09-12 | 1.2 | 1.4 | -6.5 | -11.0 |
| PSTX | 2023-09-11 | 1.2 | 1.4 | -6.6 | -11.1 |
PSTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PSTX has a Quality Grade of C, ranking ahead of 26.69% of graded US stocks.
- PSTX's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PSTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -0.612 |
| 2021-03-31 | 0 | NA | -0.563 |
| 2020-12-31 | 0 | NA | -0.678 |
PSTX Price Target
For more insight on analysts targets of PSTX, see our PSTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.67 | Average Broker Recommendation | 1.12 (Strong Buy) |
Poseida Therapeutics Inc. (PSTX) Company Bio
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Latest PSTX News From Around the Web
Below are the latest news stories about POSEIDA THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Institutional investors may adopt severe steps after Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) latest 13% drop adds to a year lossesKey Insights Significantly high institutional ownership implies Poseida Therapeutics' stock price is sensitive to their... |
Poseida Therapeutics to Present at Two Upcoming Investor ConferencesPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in September: |
News Flash: Analysts Just Made An Upgrade To Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) ForecastsPoseida Therapeutics, Inc. ( NASDAQ:PSTX ) shareholders will have a reason to smile today, with the analysts making... |
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue EstimatesPoseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2023. |
PSTX Price Returns
| 1-mo | -9.52% |
| 3-mo | -9.09% |
| 6-mo | -40.25% |
| 1-year | -37.09% |
| 3-year | -79.30% |
| 5-year | N/A |
| YTD | -64.15% |
| 2022 | -22.17% |
| 2021 | -37.92% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...